

Pacira Pharmaceuticals, Inc.  
 Form 4  
 July 15, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
 Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
**PATOU GARY**

(Last) (First) (Middle)

**C/O MPM ASSET  
 MANAGEMENT, 601 GATEWAY  
 BLVD., SUITE 350**

(Street)

**SOUTH SAN  
 FRANCISCO, CA 94080**

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
**Pacira Pharmaceuticals, Inc. [PCRX]**

3. Date of Earliest Transaction  
 (Month/Day/Year)  
**07/14/2014**

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director  10% Owner  
 Officer (give title below)  Other (specify below)  
**Chief Medical Officer**

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) |   |        | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |            |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--------|---|--|-----------------------------------|------------|
|                                 |                                      |  |                                | Code  | V | Amount |   |  |                                   | (A) or (D) |
| Common Stock                    | 07/14/2014                           |  | M <sup>(1)</sup>               |   |   | 2,460  | \$ 1.61   | 2,460  | D                                 |            |
| Common Stock                    | 07/14/2014                           |  | M <sup>(1)</sup>               |   |   | 20,237 | \$ 5.49   | 22,697   | D                                 |            |
| Common Stock                    | 07/14/2014                           |  | M <sup>(1)</sup>               |   |   | 7,303  | \$ 10.81  | 30,000   | D                                 |            |
| Common Stock                    | 07/14/2014                           |  | S <sup>(1)</sup>               |   |   | 27,593 | \$ 86.91  | 2,407  | D                                 |            |

Edgar Filing: Pacira Pharmaceuticals, Inc. - Form 4

|              |            |                         |       |   |             |     |   |                         |
|--------------|------------|-------------------------|-------|---|-------------|-----|---|-------------------------|
| Common Stock | 07/14/2014 | <u>S</u> <sup>(1)</sup> | 2,107 | D | \$<br>87.58 | 0   | D |                         |
| Common Stock |            |                         |       |   | <u>(3)</u>  |     |   | See Footnote <u>(4)</u> |
| Common Stock |            |                         |       |   |             | 702 | I |                         |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Amount or Number of Shares |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|-------------------------------|
| Stock Option (Right to Buy)                | \$ 1.61  | 07/14/2014                           |  | <u>M</u> <sup>(1)</sup>        | 2,460   | <u>(5)</u> 09/02/2020                                    | Common Stock  | 2,460                         |
| Stock Option (Right to Buy)                | \$ 5.49  | 07/14/2014                           |  | <u>M</u> <sup>(1)</sup>        | 20,237  | <u>(6)</u> 12/29/2020                                    | Common Stock  | 20,237                        |
| Stock Option (Right to Buy)                | \$ 10.81   | 07/14/2014                           |  | <u>M</u> <sup>(1)</sup>        | 7,303   | <u>(7)</u> 06/05/2022                                    | Common Stock  | 7,303                         |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |                       |       |
|--|---------------|-----------|-----------------------|-------|
|  | Director      | 10% Owner | Officer               | Other |
| PATOU GARY<br>C/O MPM ASSET MANAGEMENT<br>601 GATEWAY BLVD., SUITE 350 |               |           | Chief Medical Officer |       |

SOUTH SAN FRANCISCO, CA 94080

## Signatures

/s/ Gary Patou

07/15/2014

\_\_Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
  - \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This transaction was pursuant to a 10b5-1 Plan dated March 11, 2014.  
Represents weighted average sales price. The shares were sold at prices ranging from \$86.50 to \$87.49. The Reporting Person will
  - (2) provide upon request, to the SEC, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price.  
Represents weighted average sales price. The shares were sold at prices ranging from \$87.52 to \$87.64. The Reporting Person will
  - (3) provide upon request, to the SEC, the Issuer or any securityholder of the Issuer, full information regarding the number of shares sold at each separate price.
  - (4) Shares held by Patou Family Trust, of which the reporting person is trustee.
  - (5) 25% of the option shares vested on September 2, 2011 and the remaining 75% of the option shares vest monthly over the next 36 months. The option shares become exercisable when vested.
  - (6) 25% of the option shares vested on December 29, 2011 and the remaining 75% of the option shares vest monthly over the next 36 months. The option shares become exercisable when vested.
  - (7) 25% of the option shares vested on June 5, 2013 and the remaining 75% of the option shares vest monthly over the next 36 months. The option shares become exercisable when vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.